NOVARTIND2,420.80

Novartis India Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Returns
Return on Common Equity13.3311.4412.85
Return on Assets10.529.2110.65
Return on Capital Employed7.178.1611.07
Return on Invested Capital6.209.42
Margins
EBITDA Margin17.1819.4825.66
Operating Margin15.5818.7025.05
Incremental Operating Margin-8.31125.38
Pretax Margin30.4636.6636.61
Net Income Margin27.2925.4228.32
Additional
Effective Tax Rate10.4230.6522.63
Sustainable Growth Rate13.3311.4412.85
Incremental Operating Margin %-8.31125.38
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.